1. In Vivo
  2. >>Leadership

‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute

CDC Puts Yearly Infections At 35,000

 
• By William Masters

Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.

HIV Cells
The 'Other' Epidemic Still Lingers On • Source: Alamy

Forty years after it emerged, the HIV epidemic is still very much alive. In the US, despite progress and a variety of treatment and prevention options, new HIV infections have plateaued at around 35,000 per year according to the US Center for Disease Control and Prevention (CDC). Strikingly, around half of infections occur in just 50 of the over 3,000 counties in the US.

Ironically, one reason the virus perseveres is because of improvement in treatment. “It’s good news on the technology front that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.